Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer

A Sandoo, GD Kitas, AR Carmichael - Anticancer Research, 2014 - ar.iiarjournals.org
Background: Breast cancer is the most common cancer in females in the UK and has greater
severity in patients who overexpress human epidermal growth receptor 2 (HER2) proteins in …

Breast cancer therapy and cardiovascular risk: focus on trastuzumab

A Sandoo, GD Kitas, AR Carmichael - Vascular health and risk …, 2015 - Taylor & Francis
Breast cancer is the most common cancer in the UK. Advances in the methods of early
diagnosis as well as newer and more effective treatments have led to improvements of …

Trastuzumab cardiotoxicity: from clinical trials to experimental studies

BT Nemeth, ZV Varga, WJ Wu… - British journal of …, 2017 - Wiley Online Library
Epidermal growth factor receptor‐2 (HER‐2) is overexpressed in 20 to 25% of human breast
cancers, which is associated with aggressive tumour growth and poor prognosis …

Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer

S Nowsheen, PV Viscuse, CC O'Sullivan… - Current breast cancer …, 2017 - Springer
Abstract Purpose of Review Treatment with trastuzumab is a cornerstone of human
epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but …

[HTML][HTML] The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure

JR Walker, PK Singal, DS Jassal - Experimental & Clinical …, 2009 - ncbi.nlm.nih.gov
Breast cancer, a leading cause of increased morbidity and mortality among women,
overexpresses the human epidermal growth factor receptor 2 in approximately 20% to 30 …

Trastuzumab and cardiac dysfunction: update on preclinical studies

PM Klein, N Dybdal - Seminars in oncology, 2003 - Elsevier
Trastuzumab, a humanized, recombinant antibody directed against HER2, can significantly
improve survival in women with HER2-positive metastatic breast cancer. Treatment with …

Cardiac dysfunction associated with trastuzumab

KL Smith, C Dang, AD Seidman - Expert opinion on drug safety, 2006 - Taylor & Francis
The HER2/neu gene is amplified in∼ 25% of breast cancers, leading to HER2 protein
overexpression and shortened overall survival and time to relapse. Trastuzumab is a …

[HTML][HTML] The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment

M Lin, W Xiong, S Wang, Y Li, C Hou, C Li… - Frontiers in …, 2022 - frontiersin.org
In recent years, the incidence of breast cancer has been increasing on an annual basis.
Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human …

Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer

D Naumann, V Rusius, C Margiotta, A Nevill… - Anticancer …, 2013 - ar.iiarjournals.org
Background: Trastuzumab may improve disease-free survival after chemotherapy for HER2-
positive breast cancer. However, it carries a risk of cardiotoxicity and counseling patients …

Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial

AA Kirkham, E Pituskin, RB Thompson… - European Heart …, 2022 - academic.oup.com
Aims An improved understanding of the pathophysiology of trastuzumab-mediated
cardiotoxicity is required to improve outcomes of patients with human epidermal growth …